Search

Displaying results 1851 - 1860 of 4234 in total
  1. Drug

    Aminophylline

    go.drugbank.com/drugs/DB01223
    ApprovedInvestigational

    Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma, chronic bronchitis, and COPD. … Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.

  2. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative

  3. Drug

    Evolocumab

    go.drugbank.com/drugs/DB09303
    ApprovedInvestigational

    It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies.

  4. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. … Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.

  5. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

  6. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . … The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis.

  7. Drug

    Clarithromycin

    go.drugbank.com/drugs/DB01211
    ApprovedInvestigational

    Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with am...

  8. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

  9. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

  10. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    [A191721,L12090] Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.[A191724,A191958,A191961]